Evidence map›Paper›PMID 41085851›Full record

ArticleHuman cell2025

Long non-coding RNA FEZF1-AS1 suppresses ferroptosis in multiple myeloma cells through KIAA1429-mediated m6A modification.

Qing Su, Weiliang Liu, Peijin Wang, Mingyi Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Emerging roles of RNA mInternational journal of oncology · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qing SuDepartment of Bone Oncology, Yantai Shan Hospital, Yantai, 264001, China.
Weiliang LiuDepartment of Orthopedics, Qingdao Fifth People's Hospital, Qingdao, 266000, China.
Peijin WangDepartment of Rehabilitation, The Fifth People's Hospital of Shunde District, No. 39 Donghua Road, Longjiang Town, Shunde District, Foshan, 528300, Guangdong, China.
Mingyi WangDepartment of Rehabilitation, The Fifth People's Hospital of Shunde District, No. 39 Donghua Road, Longjiang Town, Shunde District, Foshan, 528300, Guangdong, China. wangmingyi_med@163.com.ORCID http://orcid.org/0009-0002-0145-9158

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is a hematologic malignancy characterized by abnormal clonal plasma cells in the bone marrow. This study aims to investigate the mechanism by which the long non-coding RNA FEZF1 antisense RNA 1 (FEZF1-AS1) regulates ferroptosis in MM cells through KIAA1429-mediated N6-methyladenosine (m6A) modification, and to identify novel therapeutic targets for MM therapy. The expression levels of FEZF1-AS1, Vir-like m6A methyltransferase associated protein (KIAA1429, also known as also known as VIRMA), and OTU deubiquitinase, ubiquitin aldehyde-binding 1 (OTUB1) were detected by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot analysis. Cellular viability, reactive oxygen species (ROS) accumulation, glutathione (GSH) levels, ferrous iron (Fe

Indexed as

AdenosineFerroptosisMethyltransferasesMultiple MyelomaRNA, Long NoncodingCell Line, TumorHumansReactive Oxygen SpeciesAdenosineMethyltransferasesN-methyladenosineReactive Oxygen SpeciesRNA, Long NoncodingFerroptosisKIAA1429LncRNA FEZF1-AS1Multiple myelomaOTUB1

Identifiers

PMID41085851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.